Logo image of PHIO

PHIO PHARMACEUTICALS CORP (PHIO) Stock Price, Quote, News and Overview

NASDAQ:PHIO - Nasdaq - US71880W5013 - Common Stock - Currency: USD

1.67  -0.05 (-2.91%)

After market: 1.67 0 (0%)

PHIO Quote, Performance and Key Statistics

PHIO PHARMACEUTICALS CORP

NASDAQ:PHIO (2/21/2025, 8:00:01 PM)

After market: 1.67 0 (0%)

1.67

-0.05 (-2.91%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High10.35
52 Week Low1.53
Market Cap7.98M
Shares4.78M
Float4.76M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE0.05
Earnings (Next)03-31 2025-03-31/amc
IPO05-10 2012-05-10


PHIO short term performance overview.The bars show the price performance of PHIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

PHIO long term performance overview.The bars show the price performance of PHIO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PHIO is 1.67 USD. In the past month the price decreased by -28.63%. In the past year, price decreased by -77.51%.

PHIO PHARMACEUTICALS CORP / PHIO Daily stock chart

PHIO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About PHIO

Company Profile

PHIO logo image Phio Pharmaceuticals Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Marlborough, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2012-05-10. Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Company Info

PHIO PHARMACEUTICALS CORP

11 Apex Drive, Suite 300A, Pmb 2006

Marlborough MASSACHUSETTS 01752 US

CEO: Gerrit Dispersyn

Employees: 9

Company Website: https://phiopharma.com/

Investor Relations: http://investors.phiopharma.com/investor-relations

Phone: 15087673861

PHIO PHARMACEUTICALS CORP / PHIO FAQ

What is the stock price of PHIO PHARMACEUTICALS CORP today?

The current stock price of PHIO is 1.67 USD. The price decreased by -2.91% in the last trading session.


What is the ticker symbol for PHIO PHARMACEUTICALS CORP stock?

The exchange symbol of PHIO PHARMACEUTICALS CORP is PHIO and it is listed on the Nasdaq exchange.


On which exchange is PHIO stock listed?

PHIO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PHIO PHARMACEUTICALS CORP stock?

7 analysts have analysed PHIO and the average price target is 36.72 USD. This implies a price increase of 2098.8% is expected in the next year compared to the current price of 1.67. Check the PHIO PHARMACEUTICALS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PHIO PHARMACEUTICALS CORP worth?

PHIO PHARMACEUTICALS CORP (PHIO) has a market capitalization of 7.98M USD. This makes PHIO a Nano Cap stock.


How many employees does PHIO PHARMACEUTICALS CORP have?

PHIO PHARMACEUTICALS CORP (PHIO) currently has 9 employees.


What are the support and resistance levels for PHIO PHARMACEUTICALS CORP (PHIO) stock?

PHIO PHARMACEUTICALS CORP (PHIO) has a support level at 1.66 and a resistance level at 1.84. Check the full technical report for a detailed analysis of PHIO support and resistance levels.


Should I buy PHIO PHARMACEUTICALS CORP (PHIO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PHIO PHARMACEUTICALS CORP (PHIO) stock pay dividends?

PHIO does not pay a dividend.


When does PHIO PHARMACEUTICALS CORP (PHIO) report earnings?

PHIO PHARMACEUTICALS CORP (PHIO) will report earnings on 2025-03-31, after the market close.


What is the Price/Earnings (PE) ratio of PHIO PHARMACEUTICALS CORP (PHIO)?

PHIO PHARMACEUTICALS CORP (PHIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.28).


What is the Short Interest ratio of PHIO PHARMACEUTICALS CORP (PHIO) stock?

The outstanding short interest for PHIO PHARMACEUTICALS CORP (PHIO) is 2.09% of its float. Check the ownership tab for more information on the PHIO short interest.


PHIO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PHIO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PHIO. While PHIO has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PHIO Financial Highlights

Over the last trailing twelve months PHIO reported a non-GAAP Earnings per Share(EPS) of -13.28. The EPS increased by 12.83% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -126.5%
ROE -150%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%84.99%
Sales Q2Q%N/A
EPS 1Y (TTM)12.83%
Revenue 1Y (TTM)N/A

PHIO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to PHIO. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners15.98%
Ins Owners0.32%
Short Float %2.09%
Short Ratio0.01
Analysts
Analysts82.86
Price Target36.72 (2098.8%)
EPS Next Y70.93%
Revenue Next YearN/A